Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Feb;146(2):430-41.e6.
doi: 10.1053/j.gastro.2013.10.058. Epub 2013 Nov 1.

Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV genotype-1 Infection: A Phase IIb Trial

Affiliations
Clinical Trial

Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV genotype-1 Infection: A Phase IIb Trial

Stefan Zeuzem et al. Gastroenterology. .

Abstract

Background & aims: Simeprevir (TMC435) is an oral NS3/4 protease inhibitor in phase III trials for chronic hepatitis C virus (HCV) infection. We performed a phase IIb, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the combination of simeprevir, peginterferon-α2a (PegIFN), and ribavirin (RBV) in patients with HCV genotype-1 infection previously treated with PegIFN and RBV.

Methods: We analyzed data from patients who did not respond (null response), had a partial response, or relapsed after treatment with PegIFN and RBV, randomly assigned to receive simeprevir (100 or 150 mg, once daily) for 12, 24, or 48 weeks plus PegIFN and RBV for 48 weeks (n = 396), or placebo plus PegIFN and RBV for 48 weeks (n = 66). All patients were followed for 24 weeks after planned end of treatment; the primary end point was the proportion of patients with sustained virologic response (SVR; undetectable HCV RNA) at that time point.

Results: Overall, rates of SVR at 24 weeks were significantly higher in the groups given simeprevir than those given placebo (61%-80% vs 23%; P < .001), regardless of prior response to PegIFN and RBV (simeprevir vs placebo: prior null response, 38%-59% vs 19%; prior partial response, 48%-86% vs 9%; prior relapse, 77%-89% vs 37%). All groups had comparable numbers of adverse events; these led to discontinuation of simeprevir or placebo and/or PegIFN and RBV in 8.8% of patients given simeprevir and 4.5% of those given placebo.

Conclusions: In treatment-experienced patients, 12, 24, or 48 weeks simeprevir (100 mg or 150 mg once daily) in combination with 48 weeks PegIFN and RBV significantly increased rates of SVR at 24 weeks compared with patients given placebo, PegIFN, and RBV and was generally well tolerated. ClinicalTrials.gov number: NCT00980330.

Keywords: AE; Clinical Trial; DAA; Direct-Acting Antivirals; EOT; FSS; Fatigue Severity Scale; HCV; PegIFN; PegIFN-α; RBV; RVR; SVR; SVR24; adverse event; end of treatment; hepatitis C virus; peginterferon-α; peginterferon-α2a; rapid virologic response; ribavirin; sustained virologic response; sustained virologic response at 24 weeks after the planned end of treatment.

Similar articles

See all similar articles

Cited by 74 articles

See all "Cited by" articles

Publication types

MeSH terms

Associated data

Feedback